EGFR TKIs inhibitors are the most used targeted agents in ongoing trials, specifically the third-generation agent osimertinib for its high CNS activity and efficacy in treatment-resistant, EGFR-mutant NSCLC (NCT03769103 [43], NCT02736513 [44], NCT05104281 [45], NCT02971501 [46], NCT03497767 [47], NCT03257124 [48], NCT04233021 [49]). Here, EGFR is linked to non-small cell lung carcinoma.